News related to
smart

The Korea Composite Stock Price Index touched 8,001.40 in early trade at about 9.15am, extending a rally that has accelerated since early May as investors crowded into semiconductor, memory-chip and data-centre supply chain stocks. The move marked another symbolic milestone for a market that only passed 7,000 seven trading sessions earlier, reflecting the speed with which capital has moved into companies expected to benefit from the AI infrastructure boom.

Traders at Hana Bank’s dealing room in Seoul marked the 8,000-point breakthrough with a ceremony, underscoring the psychological importance of the level for domestic investors. Yet the celebration was tempered by sharp volatility later in the session, as profit-taking and foreign selling hit several of the same technology and auto counters that had led the advance.

Samsung Electronics and SK Hynix remain at the centre of the rally. The two chipmakers have benefited from global demand for high-bandwidth memory, advanced storage and server components used in artificial intelligence training and inference. SK Hynix has strengthened its position in high-bandwidth memory supplied to leading AI chip platforms, while Samsung has drawn renewed investor attention as it pushes to close the gap in next-generation memory products and expand foundry capacity.

The broader appeal of South Korean equities has also been reinforced by expectations that the country’s corporate governance reforms will improve shareholder returns. Measures aimed at narrowing the long-standing valuation discount on local shares, including stronger pressure for dividends, buybacks and more transparent capital allocation, have encouraged investors to look beyond chipmakers into financials, industrials and holding companies.

Market participants said the scale of the advance has created a difficult balance for policymakers and investors. Strong earnings momentum and the AI investment cycle provide support for valuations, but the pace of gains has left the Kospi vulnerable to sudden reversals whenever global technology sentiment weakens. Concerns over crowded positioning, high expectations for AI-related revenue and the concentration of gains in a small group of heavyweight stocks have grown more visible as the index moved through successive records.

The Kospi’s rise has unfolded against a favourable global backdrop. Wall Street’s major indices advanced overnight, led by technology shares, while investor confidence was helped by signs of diplomatic engagement between Washington and Beijing. South Korea’s export-driven economy remains closely tied to global electronics demand, making its equity market highly sensitive to sentiment around chips, cloud computing, smartphones and consumer electronics.

Foreign flows have played a decisive role. Overseas investors have treated Seoul as a liquid way to gain exposure to AI infrastructure without relying solely on US-listed software and chip-design companies. That has lifted trading volumes and strengthened the won at times, although the currency remains exposed to shifts in US interest-rate expectations and geopolitical risks in the Middle East.

Domestic retail investors have also returned to the market in force. The rapid climb has revived comparisons with earlier speculative cycles, but the current rally is more closely tied to corporate earnings upgrades in semiconductors and technology hardware. Brokerages have raised target prices for key chip stocks, citing memory pricing, AI server demand and stronger capital expenditure by global technology companies.

Still, risks are building. A sharp fall after the 8,000-point breach showed how quickly sentiment can turn when valuations look stretched. Heavy foreign selling, particularly in technology and auto shares, pointed to caution after months of gains. Analysts have warned that any slowdown in AI spending, weaker guidance from major US technology firms or delays in high-bandwidth memory certification could trigger further volatility.

Powered by interactive tools, strategic insights and guided learning, “Shining in Global Futures” equips participants with practical tools, market insights and guided learning to better understand and navigate global futures trading. Aligned with Kenanga Futures’ motto of “Building a Smart Derivatives Trading Community”, the campaign combines education, risk awareness and seamless market access to promote confident and responsible engagement in CME-listed derivatives.

“As global markets become increasingly dynamic, navigating volatility requires more than just access, it demands insights, discipline, and confidence. Against this backdrop, ‘Shining in Global Futures’, aims to make global futures markets more accessible while equipping traders with the K-Economy they need to manage risk and participate more effectively in,” said Azila Abdul Aziz, Chief Executive Officer/ Executive Director and Head of Listed Derivatives of Kenanga Futures.

To encourage broader participation, account opening fees during the campaign period are reduced to a nominal RM10, significantly lowering the barrier of entry for newcomers to capitalise on the current market landscape. Participants will also stand a chance to win prizes with a total value of up to RM20,000 across all winners.

The first 20 participants with successful account openings who trade a minimum of 30 CME products will be entitled to RM500 Poh Kong Gold cash vouchers, while the top three traders with the highest trading volumes exceeding 100 CME contracts will be rewarded with a cumulative total of RM9,000 worth of Poh Kong Gold cash vouchers.

In addition, the campaign introduces a virtual trading challenge conducted on the enhanced Kenanga Futures Virtual Trading platform (“KFVT“), which allows participants to experience real‑time market conditions and compete for rewards without incurring actual trading risk. Designed with accessibility in mind, KFVT also provides a practical and engaging entry point for new traders to gain hands‑on exposure, test strategies, and build confidence in navigating global markets. As part of this challenge, the top 10 participants who achieve the highest simulated profits will receive RM100 e‑shopping vouchers.

Looking ahead, Kenanga Futures plans to expand this initiative over the next year with the inclusion of advanced modules, collaborative learning opportunities and partnerships with industry leaders, as it continues its commitment to creating a thriving community of informed, confident and future-ready traders. Visit https://www.kenangafutures.com.my/shining-in-global-futures/ to start your trading journey today.

-Terms and conditions apply.

Hashtag: #KenangaFutures

The issuer is solely responsible for the content of this announcement.

KENANGA FUTURES SDN BHD

Kenanga Futures Sdn Bhd is an award-winning Malaysian listed derivatives broker regulated under the Securities Commission Malaysia and Bursa Malaysia Berhad. The company offers clients electronic market access to trade listed products on Bursa Malaysia Derivatives and CME Group. Apart from being a direct member of Bursa Malaysia Derivatives Berhad and the clearinghouse, the company is also a registered broker with the U.S. CFTC and was granted exemption relief pursuant to Commission Regulation 30.10 which enables the company to paper directly with entities in the U.S. On the domestic front, the company has an extensive network with 16 branches nationwide licensed to trade listed derivatives.

Clients can access both U.S. and Malaysian listed derivatives on a single trading platform via the company’s trademarked real-time customised online trading solution, KDF TradeActive™. KDF TradeActive™ is available on both desktop and mobile devices, giving clients easy access to real-time market data and flexibility to trade on-the-go.

This Press Release was issued by Kenanga Group’s Marketing, Communications & Sustainability Department.

By Nitya Chakraborty The developments in eastern and north eastern parts of India are getting increasing attention from Washington in the context of China’s planned moves to expand its control in Bangladesh and Myanmar, the two countries bordering the Indian states.US President Donald Trump’s unusual message sent to the Indian Prime Minister Narendra Modi on […]

The article North East India Is Emerging As The Battle Ground For Power Between U.S. And China appeared first on Latest India news, analysis and reports on Newspack by India Press Agency).

Taking place from May 12-14, 2026, the co-located events are expected to welcome 8,000 industry professionals from over 90 countries and regions. Spanning more than 30,000 sqm, the exhibition features over 150 brands showcasing next-generation technologies, immersive solutions, and digital infrastructure across the sector.

Against the backdrop of an estimated ~8% annual growth trajectory in Asia’s integrated resorts sector, according to a 2025 report by Research and Markets, the event underscores the region’s accelerating role as a global growth engine, where technology innovation and rising demand are increasingly converging.

Reflecting this shift, “Asia’s integrated resorts sector is entering a pivotal phase of transformation, as markets across the region continue to evolve with a broader mix of tourism, entertainment and lifestyle experiences,” said Yip Je Choong, Senior Vice President, Commercial, APAC, RX (Reed Exhibitions). “With G2E Asia and Asian IR Expo co-located, we are creating a platform that brings together stakeholders across the value chain to support innovation, collaboration and long-term, sustainable growth.”

Across the exhibition floor and conference programs, key industry leaders are actively engaging with peers to exchange insights and explore new opportunities for collaboration.

Leading Industry Figures Mark Opening Ceremony

The opening ceremony, held in the Expo Hall, officially marked the commencement of G2E Asia + Asian IR Expo 2026, with senior industry figures from across gaming, hospitality, and entertainment in attendance.

Guests included: (List to be provided)

Their participation reflects the industry’s sustained engagement and long-term commitment to advancing innovation across integrated resorts, gaming, and entertainment ecosystems.

Conference Programs Led by Global Industry Voices

G2E Asia and Asian IR Expo each feature dedicated three-day programs led by senior industry figures addressing technologies, regulations, and market forces shaping the sector’s future.

On Tuesday, May 12, Mr. Grant Chum, Chief Executive Officer and Executive Director of Sands China Ltd., delivers the opening keynote for G2E Asia Conference and Asian IR Summit, setting the strategic tone with insights into global industry trends shaping gaming and entertainment.

On Thursday, May 14, Mr. Mario Yau Kwan Ho, Chairman and Co-Chief Executive Officer of NIP Group INC., and Co-owner of Boston Celtics, is set to present a keynote for Asian IR Summit, offering perspectives on global market shifts and the evolving integrated resorts landscape.

Across both programs, speakers include:

• Mr. Adrian Lee, Head of Sales, Google Customer Solutions, Hong Kong & Macau, Google
• Mr. AI Watson, Chief Executive Officer, Dataworks Group
• Mr. Alan Teo, Chief Executive Officer, Hoiana Resort & Golf
• Mr. Cheng Wai Tong, Deputy Director, Macao Government Tourism Office
• Mr. Gregory Hawkins, President and Chief Operating Officer, Solaire
• Mr. Joseph Bufalino, Executive Director of Responsible Gambling, Marina Bay Sands
• Mr. Kenneth Feng, Chief Executive Officer and Executive Director, MGM China Holdings Limited
• Mr. Walt Power, Chief Executive Officer, The Grand Ho Tram
• And more.

Event Highlights Across May 12-14

Across three days, the co-located event presents a curated ecosystem of exhibition, education, and industry networking experiences.

Exhibition (May 12-14)
Discover innovation across gaming, entertainment, and integrated resorts, with more than 150 brands spanning the full industry ecosystem.

G2E Asia Conference (May 12-14)
Access critical market insights, regulatory developments, and business opportunities across Asia from the region’s leading platform for gaming and entertainment leaders.

Asian IR Summit (May 12-14)
Explore strategic insights across hospitality, technology, sports, and entertainment with senior leaders across the evolving integrated resorts sector.

Tech Talk (May 12)
Gain actionable insights from leading experts on leveraging Artificial Intelligence, applying Machine Learning in real-world operations, and using data to drive smarter, more profitable decisions.

May 12 Slots Networking:
Engage in exclusive roundtables for slots operators and suppliers to co-design next-generation gaming cabinets with embedded biometric feedback.

May 12 G2E Asia After Party:
Unwind with industry peers at a Venetian-themed gala featuring a live preview of 2027’s most anticipated VR casino suite.

May 13 Table Games Networking:
Exchange insights between operators and providers on gameplay evolution, innovation, and future table game ecosystems.

Be Part of the Future of Entertainment and Integrated Resorts

Industry professionals from gaming, entertainment, and integrated resorts sectors – including operators, providers, and hospitality experts – will gain strategic insights, networking opportunities, and explore cutting-edge innovations that are shaping the future of the sector.

Registration is available online and onsite.

To learn more about G2E Asia, visit www.G2EAsia.com.
To learn more about Asian IR Expo, visit www.AsianIRExpo.com.

Hashtag: #G2EAsia #AsianIRExpo2026

The issuer is solely responsible for the content of this announcement.

World-First Innovations Showcase Hong Kong’s Thriving Life and Health Tech Ecosystem from Bench to Bedside

HONG KONG SAR – Media OutReach Newswire – 12 May 2026 – Hong Kong Science and Technology Parks Corporation (HKSTP) joined alongside 38 Park companies in the two flagship events of the 5^th International Healthcare Week — the Hong Kong International Medical and Healthcare Fair (“Medical Fair”) and the Asia Summit on Global Health (“ASGH”), held from 11 – 13 May. Showcasing at these premier medical innovation and technology (I&T) events, HKSTP is demonstrating its pivotal role in nurturing and supporting the growth of biotechnology enterprises. During ASGH, HKSTP also hosted a dedicated investor pitch session, providing Park companies with an exclusive stage to connect directly with global capital and pursue fundraising opportunities.

Over 30 Market-Ready Solutions across Four Key Industry Focus

On the opening day of the Medical Fair, the HKSTP pavilion drew numerous industry professionals, investors and professional buyers, who gathered to explore Hong Kong’s latest I&T achievements and actively discuss collaboration opportunities. Participating companies span four critical areas — health monitoring, surgical assistance, precision medicine, rehabilitation training — comprehensively demonstrating the diverse strengths of Hong Kong’s life and health technology sector as it progresses from research and development (R&D) to commercial application.

Mr Terry Wong, CEO of HKSTP, said: “HKSTP has always been a steadfast partner to tech ventures, building a vibrant and well-established ecosystem for biotech companies ranging from start-ups with early-stage innovation to experienced innovators with market-ready solutions. To meet their diverse needs, we offer end-to-end support from R&D to clinical applications, including lab facilities, funding connections and market expansion. Our presence at this event fully reflects the innovative vitality and strength of Hong Kong’s life and health tech ecosystem. We hope to showcase Hong Kong’s cutting-edge medical R&D achievements to the international community, while delivering a clear message: Hong Kong is not only a top-tier scientific research base, but also the strongest springboard for technology enterprises to go global. By uniting forces across all sectors, we will further solidify Hong Kong’s leadership as an international health tech hub.”

Park company Highlights:

• Endovision offers an intestinal endoscopic imaging system that leverages AI and real-time imaging to assist physicians in conducting more precise examinations. The solution has already obtained EU Medical Device Regulation (MDR) certification.
• Mirror Caring presents SyncKnee, a smart wearable solution integrating flexible sensors, embedded systems and AI analytics to deliver real-time monitoring of knee joint health and data-driven insights.
• Voice Empowerment Technology features a customised “AI Voice Reconstruction Tool” designed to enhance the efficiency of speech therapy services, offering breakthrough communication support for patients with aphasia and speech disorders.

“World-First” Cutting-Edge Medical Technologies Take Centre Stage

This year, HKSTP has also set up a dedicated exhibition zone at the Asia Summit on Global Health (ASGH), spotlighting a range of groundbreaking biomedical solutions, including several “world-first” innovations:

• Agilis Robotics: The world’s first robotic-assisted “En Bloc Transurethral Resection of Bladder Tumour”, achieving precise tumour resection margins and offering a minimally invasive surgical option with faster recovery for early-stage cancer patients.
• GenEditBio: The world’s first in vivo genome editing therapy (often referred to as “DNA surgery”) targeting corneal dystrophy, with Phase I clinical trials expected to commence this year, aiming to improve patients’ quality of life.
• Meta Pharmaceuticals: The world’s first oral inhibitor for treating autoimmune diseases such as inflammatory bowel disease and multiple sclerosis, enhancing medication convenience and delivering safer, more effective anti-inflammatory therapy.

Dedicated Investor Pitch Session: Connecting Global Capital to Accelerate Enterprise Growth

For early-stage biotech companies, funding is crucial to sustaining research and achieving breakthroughs. To this end, HKSTP is fulfilling its role as a “super-connector” by hosting the “Life and Health Technology Innovation Pitch” at ASGH, to bridge between Park companies and the global market and deepen international partnerships.

The pitch session bought together 12 leading global investors from the UK, the US, Singapore, Canada and beyond, creating a top-tier platform for fundraising and business matching, and accelerating the translation of life and health tech innovations. Ten Park companies with breakthrough technologies took the stage to attract international capital, further showcase their innovative solutions and advance to the next stage of growth and global expansion.

Event Details:
Hong Kong International Medical and Healthcare Fair (Medical Fair)
Date: 11–13 May 2026
Venue: Hong Kong Convention and Exhibition Centre, Hall 3DE
HKSTP Booth: 3E-E06

Asia Summit on Global Health (ASGH)
Date: 11–12 May 2026
Venue: Hong Kong Convention and Exhibition Centre, Hall 3FG
HKSTP Booth: 3F-A11
Hashtag: #HKSTP

The issuer is solely responsible for the content of this announcement.

About Hong Kong Science and Technology Parks Corporation

Hong Kong Science and Technology Parks Corporation (HKSTP) was established in 2001 to create a thriving I&T ecosystem grooming 13 unicorns, more than 17,000 research professionals and over 2,500 technology companies from 26 countries and regions focused on developing healthtech, AI and robotics, fintech and smart city technologies, etc.

Our growing innovation ecosystem offers comprehensive support to attract and nurture talent, accelerate and commercialise innovation for technology ventures, with the I&T journey built around our key locations of Hong Kong Science Park in Pak Shek Kok, InnoCentre in Kowloon Tong and three modern InnoParks in Tai Po, Tseung Kwan O and Yuen Long realising a vision of new industrialisation for Hong Kong, where sectors including advanced manufacturing, micro-electronics and biotechnology are being reimagined.

Hong Kong Science Park Shenzhen Branch in Futian, Shenzhen plays positive roles in connecting the world and the mainland with our proximity, strengthening cross-border exchange to bring advantages in attracting global talent and allowing possibilities for the development of technology companies in seven key areas: Medtech, big data and AI, robotics, new materials, microelectronics, fintech and sustainability, with both dry and wet laboratories, co-working space, conference and exhibition facilities, and more.

Through our R&D infrastructure, startup support and enterprise services, commercialisation and investment expertise, partnership networks and talent traction, HKSTP continues to contribute in establishing I&T as a pillar of growth for Hong Kong.

More information about HKSTP is available at www.hkstp.org.

Richard Cheng, Associate Commercial Director (Hong Kong & Macau) at BeOne, said: “We are honored to receive this award from the Hong Kong Commercial Times. BeOne has built differentiated capabilities across clinical development and manufacturing, supported by a broad and diverse R&D pipeline. In Hong Kong, we have introduced several therapies, including BTK, PD-1 and IL-6 inhibitors. Looking ahead, we will continue to advance our plans in Hong Kong by leveraging opportunities enabled by the ‘1+’ policy and the planned establishment of the Hong Kong Centre for Medical Products Regulation (CMPR) and its ‘primary evaluation’ mechanism. Supported by our global supply network, we aim to bring additional medicines to patients in Hong Kong and the Greater Bay Area and help improve access to treatments aligned with international standards.”

Global R&D and Innovation

Founded in 2010, BeOne is focused on accelerating key stages of oncology innovation—from discovery through development to patient access. Through an integrated model spanning R&D, manufacturing and commercialization, the company works to translate innovation into clinical value. Today, BeOne operates across six continents in more than 45 markets and is supported by more than 1,200 oncology R&D professionals.

BeOne’s R&D platform has advanced more than 35 clinical-stage drug candidates, including three internally developed products that have received commercial approval, reaching more than 2 million patients worldwide.

Pipeline Highlights

BeOne continues to expand its global footprint through a portfolio of internally developed products, including:

• BTK Inhibitor: As the company’s first self-developed innovative drug, it holds a significant position in the global market (including Hong Kong), particularly in the field of B-cell malignancies.
• PD-1 Inhibitor: Launched in more than 50 markets worldwide, reaching 1.8 million people. In Hong Kong, it has been approved for six indications, including immunotherapy for lung, esophageal and gastric cancers.
• Next-Generation BCL-2 Inhibitor: Approved for certain lymphoma indications in Mainland China. It has been granted Priority Review by the U.S. Food and Drug Administration, and a marketing application has been submitted in the European Union.

Manufacturing Network Supporting Global Supply

BeOne maintains an integrated chain from R&D to manufacturing and commercialization, supported by production sites in the United States and China designed to help maintain a stable global supply:

• New Jersey, U.S.: A North America biologics hub integrating manufacturing and clinical R&D. The site spans 1.82 million square feet, including a dedicated 400,000-square-foot production facility.
• Suzhou, China (small molecule manufacturing): Supports clinical and commercial-scale production in accordance with applicable FDA, EMA and GMP requirements.
• Guangzhou, China (biologics and ADC manufacturing): A 1.3 million-square-foot facility supporting R&D and production of antibody-drug conjugates (ADCs) and serving as a supply hub for the Greater Bay Area, including Hong Kong.

BeOne has also been recognized by industry organizations for its innovation, including being named one of the “Top 10 Most Inventive” pharmaceutical companies by IDEA Pharma in 2025^[1]. The company will continue to advance programs in hematologic malignancies and solid tumors, with Hong Kong serving as a strategic hub to support the delivery of innovative therapies globally.

1. 2025 Pharmaceutical Innovation and Invention Index, IDEA Pharma

This material is intended for the purpose of communicating disease-related knowledge and cutting-edge medical information to the public and is not intended for promotional or advertising purposes. It does not constitute a promotion or recommendation for any medication or treatment plan, nor can it serve as a substitute for the advice of medical and health professionals. If you have any questions, please consult a medical or health professional.

Hashtag: #BeOneMedicines

https://www.beonemedicines.com/

The issuer is solely responsible for the content of this announcement.

About BeOne Medicines

BeOne Medicines is a global oncology company domiciled in Switzerland, focused on discovering and developing innovative treatments designed to be more affordable and accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is advancing a diverse pipeline of novel therapeutics through internal capabilities and collaborations. With a growing global team of nearly 12,000 colleagues spanning six continents, the Company is committed to improving access to medicines for more patients. To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram.

About HKCT Business Awards 2026

Organized by the Hong Kong Commercial Times, the HKCT Business Awards is a representative annual event in the Hong Kong business community. It honors companies demonstrating excellence, innovation, and significant contributions to Hong Kong’s economy and society across dimensions including technological innovation and market competitiveness.